FNTB
Protein farnesyltransferase subunit beta
As of the edition of 20 October 2026, FNTB (protein farnesyltransferase subunit beta, UniProt P49356) has 3 drugs tested at it and 7 companies on the list, 1 on route A and 3 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P49356
- How well studied
- Drug target: an approved drug acts on it
- Solved structures
- 14
- Disease areas
- Cancer; Blood and lymph; Inherited and neonatal; Skin and connective tissue; Digestive system; Immune system; Nervous system; Lungs and airways
- Registered trials of its drugs
- 129
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Went quiet | 1 |
| Stopped | 1 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Tipifarnib | Stopped | Phase 3 | none listed |
| Lonafarnib | Marketed | Phase 3 | Ends 2027 |
| BMS-214662 | Went quiet | Phase 1 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 3 |
| Engaged | 1 |
| Undetermined | 2 |
| Total on the list | 7 |
| Company | Route |
|---|---|
| Kura Oncology | Route A |
| Sentynl Therapeutics | Route B |
| TMC Pharma | Route B |
The other 4 companies at FNTB
In the product7 companies in all; 4 are not named here, and no score is.
See the 7 companies at FNTB, ranked, with the facts behind eachRequest access. Nothing is shown until you do.